“2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements ... decisions in patients with MCL, CLL, MM and ALL Studies show depth of response ...
The results could herald a step change in treating CLL, which current treatments ... as tested by flow cytometry and/or analysis for minimal residual disease (MRD), which measures residual ...
The model incorporates residual connections and layer-wise supervision ... fluorescence signals while effectively reducing noise and artifacts that could obscure CLL-related abnormalities. Read more ...
An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to ...
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health ...
At close: March 20 at 4:00:01 PM EDT Loading Chart for ALLO ...
Pre-Market: 6:12:07 a.m. EDT Loading Chart for ALLO ...
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback